Vir en­lists J&J vet to run busi­ness de­vel­op­ment; Gilead finds Kite suc­ces­sor to Christi Shaw

→ Af­ter grab­bing $10 mil­lion in fund­ing from the Bill & Melin­da Gates Foun­da­tion for its HIV vac­cine ear­ly this month, Vir Biotech­nol­o­gy has now plucked Jeff Calcagno as EVP and CBO. Calcagno hails from J&J, hav­ing spent 12 years with the com­pa­ny. Ear­li­er last month, George Scan­gos hand­ed in his re­tire­ment pa­pers and gave the reins of Vir to Bay­er’s Mar­i­anne De Backer.

→ Gilead has now filled the va­cant seat left in the wake of Christi Shaw’s ex­it from Kite with the ap­point­ment of Cindy Perettie. Perettie joins the cell ther­a­py unit as EVP of Kite — in­stead of CEO — near­ly two months af­ter Shaw stepped down, and she will be re­port­ing di­rect­ly to Daniel O’Day. Perettie for­mer­ly served as CEO of Foun­da­tion Med­i­cine and lat­er head­ed Roche’s Mol­e­c­u­lar Lab So­lu­tions af­ter Roche bought out Foun­da­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER